-
The probability of mutation of ovarian cancer anti-cancer gene is clear
Time of Update: 2021-02-09
May 6, Fudan University Affiliated Cancer Hospital held a presentation of ovarian cancer research results, professor Wu Xiaohua led the ovarian cancer research team for many years, the first multi-center ovarian cancer embryo clinical study found that in China's ovarian cancer patients, the risk of BRCA1 and BRCA2 gene mutation in the body as high as 28.5%.
-
Genetic studies reveal the metabolic origins of anorexia
Time of Update: 2021-02-09
a global study led by researchers at King's College London and the University of North Carolina at Chapel Hill found that anorexia nerve is at least partly a metabolic disorder, rather than what was previously thought to be pure psychosis.
-
Temporary scans during prostate cancer treatment can help guide treatment
Time of Update: 2021-02-09
After two rounds of l-177 (177Lu)-PSMA radiological ligand therapy, metastatic degenerative antigen (PSMA) electron emission fault scanning (PET) imaging showed significant predictive value for patient survival.
In Phase 2 clinical trials, 177 Lu-PSMA treatments showed promising results in treating patients with metastatic desopathic prostate cancer.
-
Reduce cell manufacturing time and increase cell yield! TG Medical completes the important layout of the cell manufacturing process!
Time of Update: 2021-02-09
From the development of automated cell manufacturing technology platforms to the strengthening of the supply chain, Boya's TG Medical continues to contribute to the standardization of large-scale cell manufacturing to meet the growing market demand and ultimately improve access to cell therapy for the benefit of more patients.
-
3D bioprinting models transform cancer drug development and tumor therapy
Time of Update: 2021-02-09
In the study, recently published in Advanced Materials, Dr. Angela Panoskaltsis-Mortari, associate director of research at the University of Minnesota School of Medicine, professor of pediatrics, director of the 3D Bioprinting Equipment Department and a member of the Masonic Cancer Center, and her assistant researchers found that cells behave differently in these 3D flexible tissue environments than on 2D plastic or glass surfaces.
-
The flu Terminator? New study finds 10,000 T-cells! Universal influenza vaccine is out!
Time of Update: 2021-02-09
recently, scientists claimed to have discovered immune cells that can fight all known influenza viruses, in what has been hailed as a major breakthrough that could help develop a universal one-off vaccine against multiple diseases.
-
By sticking cytokines to tumor tissue, "tumor adhesion" helps to fight cancer with precision
Time of Update: 2021-02-09
The new study, published in the American Journal of Science Translational Medicine, shows that a protein called photoprotein polysaccharin can "limit" cytokines in solid tumor tissue, prolonging their time in killing tumors and reducing damage to healthy tissue.
-
Geneneck announces the latest results of SMA therapy in clinical trials
Time of Update: 2021-02-09
study patients with type 1 SMA were treated with different doses of risdiplam in a clinical trial called FIREFISH.
in sunFISH clinical trials, patients with type 2 and type 3 SMA between the ages of 2 and 25 were treated with risdiplam.
-
Scientists have built the first model of mitochondrial epilepsy
Time of Update: 2021-02-09
Responsional research into the importance of research, " said Mark Cunningham, professor of tyrant epilepsy neurophysiology at Ellen Mayston Bates, "We believe this is an important and novel study because it is the first time that a mitochondrial epilepsy model has been produced that captures observed features." The model provides mechanism insights to demonstrate the role of astrological glial cells in this pathological activity.
-
Fudan and Xiamen University have teamed up for the first time to develop a new strategy to stop the growth of NRAS mutant melanoma
Time of Update: 2021-02-09
Finally, they designed a STK19 inhibitor called ZT-12-037-01, which effectively blocks NRAS activation and the production of NRAS mutant melanoma in experimental animal models.
In addition, this STK19 inhibitor may provide a treatment option for 25% of cancers with RAS mutations.
-
Novart is working with academics at Oxford University on big data research and development
Time of Update: 2021-02-09
"The ability to detect patterns in diseases and detect commonality between diseases can predict how patients will respond to new and existing drugs earlier than they do now." In the long run, Thomas believes the initiative will "reform the way Novartic clinical trials are designed and implemented" and identify "new opportunities and goals" for drug development.
-
Only 44 per cent of uk's health sector trusts humans rather than artificial intelligence
Time of Update: 2021-02-09
found that 85 per cent of office workers surveyed in the healthcare and health services industry said they were not currently using any type of ARTIFICIAL, and surprisingly, almost half (49 per cent) of workers in the sector believe their employers are not ready to introduce any new AI technology next year.
-
SAGA Diagnostics drives the development of liquid biopsy technology for ultra-sensitive cancers
Time of Update: 2021-02-09
This round of investments is led by Hadean Ventures, followed by the Fårö Capital and gunnar Nilsson Cancer Foundation.
about Hadean Ventures is a life sciences company that invests in projects across Europe, with a particular focus on the Nordic region.
-
Microflow devices can obtain clusters of circulating cancer cells
Time of Update: 2021-02-09
"But we realized that if we were to understand the complex process of cancer metastasis, we needed to develop a tool to easily find these clusters." To do this, the researchers first identified the basic requirements necessary to gather useful information from isolated cancer cell populations.
-
Tecentriq and Avastin chemotherapy triplets were approved immediately
Time of Update: 2021-02-09
, the Swiss pharmaceutical giant, recently announced that the European Medicines Agency(EMA) Commission on Human Pharmaceutical Products (CHMP) has issued an active review recommending approval of the PD-L1 oncology immunotherapy Tecentriq (atezolizumab) in combination with A vastin, generic name: bevacizumab, beva monoantigen) and chemotherapy (yew alcohol and carpentry), for first-line treatment in patients with metastasis non-squamous non-small cell lung cancer (NSq NSCLC) without EGFR or ALC genomic tumor distortion.
-
PNAS: Placental stem cells contribute to the regeneration process after heart disease
Time of Update: 2021-02-09
"They can target the injured area and go directly into the damaged area through the circulatory system to repair it, and they can avoid rejection by the host immune system." team at Mount Sinai has previously found that a mixture of placental stem cells in mice can help a pregnant female's heart recover from an injury that could lead to heart failure.
-
Nobel Prize-winning technology is helping stem cell-induced CAR-T therapy
Time of Update: 2021-02-09
today, there is a powerful news in the industry: Takeda and Kyoto University announced that an innovative CAR-T therapy has moved from academia to industry for clinical development.
Notably, this CAR-T therapy, developed using the Nobel Prize-winning "induced erythnic stem cell technology", promises to revolution the field of cell therapy.
-
New clinical standard for RAF melanoma! The new targeted combination therapy Braftovi and Mektovi has been approved by NICE UK
Time of Update: 2021-02-09
France's Pierre Fabre recently announced that the UK's National Institute for Health and Clinical Optimization (NICE) has issued guidelines recommending a combination of Braftovi (binimetinib, a MEK inhibitor) and Mektovi (a BRAf inhibitor) for the treatment of adult patients with non-removable melanoma who have been tested for the BRAF V600 mutation.
-
Fda announces pilot program to treat Duching's muscular dystrophy
Time of Update: 2021-02-09
, Wave Life Sciences announced that it has been selected for the FDA's Innovative Complex Trial Designs (CID) pilot project to validate its Phase 2/3 clinical trial project for the treatment of Duching's muscular dystrophy (DMD) in the research drug suvodirsen (WVE-210201).
-
Cell: Aiming at two neurons controls visual behavior
Time of Update: 2021-02-09
When the mice linked visual stimuli to licking behavior, the researchers identified a collection of neurons in the mice's brains that responded to vertical stripes and re-stimulated them with a double photon laser.
